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ABSTRACT
Objective: The objective of this study is to evaluate
the efficacy and safety of renal denervation in patients
with resistant hypertension.
Methods: We searched MEDLINE and EMBASE for
studies that evaluated the use of catheter-based renal
sympathetic denervation compared to a control group
and reported blood pressure results at follow-up. Data
was extracted from relevant studies and pooled
estimates for blood pressure were determined using
the inverse variance method for meta-analysis with
mean difference.
Results: We identified 12 studies (three randomised
controlled trials (n=688), eight prospective observational
studies (n=478) and one observational study with
matched controls (n=310)). Data from SYMPLICITY
HTN-3, the only high-quality blinded randomised control
trial suggests that there is no significant difference in
change in systolic (−2.30 95% CI −6.90 to 2.30 mm Hg)
or diastolic (−1.96 95% CI −4.98 to 1.06 mm Hg) blood
pressure at 6 months. The pooled data from two
unblinded trials of lower quality showed significant
reduction in change in systolic (−27.36 95% CI −37.08
to −24.61 mm Hg) and diastolic blood pressure (−9.62
95% CI −14.51 to −4.72 mm Hg). In terms of safety,
SYMPLICITY HTN-3 found no significant differences
between treatment and control group in terms of death,
myocardial infarction, new onset renal disease, stroke
and hypertensive emergencies.
Conclusions: In conclusion, while poor quality
unblinded studies provide evidence that renal denervation
using catheter-based systems is effective in reducing
systolic and diastolic blood pressure in resistant
hypertension, the largest randomised controlled trial to
date (SYMPLICITY HTN-3) failed to demonstrate any
benefit.
INTRODUCTION
Hypertension is an important risk factor for
mortality worldwide, causing an estimated
7.5 million deaths per year.1 Despite receiv-
ing hypertensive medications, only 53% of
patients with hypertension achieve the
recommended blood pressure targets,2 with
a proportion of these patients developing
resistant hypertension. Resistant hyperten-
sion is deﬁned as blood pressure that
remains above goal in spite of the concur-
rent use of three antihypertensive agents of
different classes, with one of the three agents
being a diuretic.3
There has been signiﬁcant interest in tar-
geting the renal sympathetic nervous system
in treatment of systemic hypertension.
Evidence suggests that sympathetic nervous
system over-activity is responsible for the
development and maintenance of hyperten-
sion.4 Historical observations have shown
that surgical sympathectomy can achieve
good blood pressure reduction.5 More
KEY MESSAGES
What is already known about the subject?
▸ Renal denervation has generate significant inter-
est as a method for the treatment of systemic
hypertension.
▸ Several non-blinded studies of renal denervation
have shown favourable reductions in blood
pressure.
What does this study add?
▸ The high quality SIMPLICITY HTN-3 trial, failed
to demonstrate any significant improvement in
blood pressure compared to control, whereas
meta-analysis of two RCTs without sham control
or blinding found significant reduction in BP
with renal denervation.
▸ Other non-blinded observational studies which
are at risk of bias appear to suggest that there
are significant reduction in blood pressure with
renal denervation.
How might this impact on clinical practice?
▸ Current evidence provides insufficient evidence
to support the use of renal denervation in the
treatment of resistant hypertension as the
highest quality trial failed to demonstrates this
relationship.
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recently, catheter-based renal denervation that applies
low-level radiofrequency (RF) energy to disrupt renal
sympathetic nerves within the renal artery wall has
emerged as a promising minimally invasive treatment
for hypertension. There is growing clinical evidence to
suggest that this method effectively and safely reduces
blood pressure in patients with resistant hypertension.6 7
Most recently, however, the SYMPLICITY HTN-3 single
blind randomised controlled study reported a failure to
reach its primary efﬁcacy endpoint of a reduction in
ofﬁce-based systolic blood pressure from baseline to
6 months.8 9
In view of the renewed interest around renal denerv-
ation, particularly in light of the SYMPLICITY HTN-3
trial data, we report a systematic review and
meta-analysis, which aims to evaluate the efﬁcacy of
renal denervation in the treatment of resistant hyperten-
sion over time.
METHODS
Study eligibility
Studies were considered for inclusion if they evaluated
the use of catheter-based renal sympathetic denervation
compared to a control group and reported blood pres-
sure results at follow-up. Single arm studies, case reports,
case series, letters and editorials were excluded, but rele-
vant reviews were retrieved to identify additional studies.
Search strategy
Our search was carried out using the OvidSP interface
covering MEDLINE and EMBASE from inception until
April 2014. Brown search terms were used to reduce like-
lihood of missing relevant studies (see online supple-
mentary appendix 1).
Two reviewers (CSK and SP) independently checked
retrieved titles and abstracts for eligibility, and the rele-
vant abstracts were checked by the other reviewers (YKL
and MAM). Finally, two reviewers manually searched
bibliographies of included studies, as well as full-text
review articles identiﬁed from the search (CSK and
YKL).
Data extraction
Two reviewers (CSK and SP) extracted data on study,
design, patient characteristics, treatment, follow-up and
results, and performed quality assessment of included
studies. This was checked by the other reviewers (MAM
and YKL).
Data synthesis
We planned to perform meta-analysis using RevMan
V.5.1.2 (Nordic Cochrane Centre) using the inverse vari-
ance method for mean difference if there was not more
than a moderate degree of heterogeneity. The random
effects model was used because it considers study hetero-
geneity when generating an average estimate. Statistical
heterogeneity was evaluated through the I2 statistic
where values of 30–60% were representing moderate
heterogeneity.10
Validity assessment
Validity assessment was performed by considering use of
blinding, outcome ascertainment, baseline differences,
loss to follow-up and selective reporting. A subjective
overall risk of bias was also assigned for each study based
on these factors. In addition, we planned to conduct
asymmetry testing for publication bias provided that
there were >10 studies in the meta-analysis and if statis-
tical heterogeneity was <50%.11
RESULTS
Twelve studies met the inclusion criteria (study selection
is shown in online supplementary appendix 2). These
studies included three randomised controlled trials,7–9 12
eight prospective observational studies6 13–19 and one
observational study with matched controls20 with a total
of 1556 participants (table 1). In general, the participant
selection criteria were similar across all but one study
that randomised patients with atrial ﬁbrillation to renal
denervation and pulmonary isolation versus pulmonary
isolation alone.12
The risk of bias assessment is shown in online supple-
mentary appendix 3. All included studies were non-
blinded except for SYMPLICITY HTN-3. The majority of
studies were deemed to be of at least moderate risk of
bias. Two studies were only available in abstract form
and were deemed to be at high risk of bias.
The renal denervation procedures, control group,
follow-up and results are shown in table 2. The majority
of studies used the SYMPLICITY catheter system by
Medtronic with multiple ablations in both renal arteries.
All except two studies did not describe in detail the
management received by the control group. In the
matched observational study,20 normotensive and con-
trolled blood pressure controls from the Australian
Diabetes, Obesity and Lifestyle database were used. In
another randomised trial of patients with atrial ﬁbrilla-
tion, patients were randomised to pulmonary vein isola-
tion alone or in combination with renal denervation. All
studies included reported increased reductions in sys-
tolic and diastolic blood pressure with renal denervation
therapy, compared to controls.
Three randomised controlled trials were considered
for meta-analysis. However, there was signiﬁcant statis-
tical heterogeneity when pooling the three randomised
controlled trials and it was decided that the two
unblinded trials (of moderate-high risk of bias) would
be considered separately from the higher quality trial
that had used a sham procedure as placebo. Data from
SYMPLICITY HTN-3, the only high-quality blinded ran-
domised control trial, suggests that there was no signiﬁ-
cant difference in change in systolic (−2.30 95% CI
−6.90 to 2.30 mm Hg) or diastolic (−1.96 95% CI −4.98
to 1.06 mm Hg) blood pressure at 6 months. The pooled
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Table 1 Study design, patient characteristics of parallel group studies of renal denervation versus control in resistant hypertension
Design Year Country
Number
of participants
(treatment, control) Mean age
Per cent
male Selection criteria and management
Clinical trials
Pokushalov
et al12
Randomised trial NA Russia, The
Netherlands and
USA
27 (13, 14) 56 and
57 years
78 Drug-refractory AF or paroxysmal AF, with
BP ≥160 mm Hg (≥150 mm Hg with type 2
diabetes) with at least 3 antihypertensive
drugs and eGFR ≥45 mL/min/1.73m2.
Diuretics were used in 96% of patients.
Patients with secondary causes of
hypertension were excluded
SYMPLICITY
HTN-27
Randomised trial June 2009 to
January 2010
Europe,
Australia and
New Zealand
106 (52, 54) 58 years 58 Age >18 years with BP ≥160 mm Hg
(≥150 mm Hg with type 2 diabetes) with at
least 3 antihypertensive drugs. Diuretics
were used in 90% of patients. Patients with
significant renal artery stenosis or renal
artery anatomy that precluded treatment
were excluded
SYMPLICITY
HTN-38 9
Randomised trial September
2011 to
January 2014
International 535 57 years 61 Age ≥18 and ≤80 years on stable medical
regimen of ≥3 antihypertensives. Office BP
≥160 mm Hg on average of 3 readings on
initial screening and confirmatory screening.
Exclusions: eGFR<45 mL/min/1.73 m2,
ambulatory blood pressure monitoring
average <135 mm Hg, type 1 diabetes,
chronic oxygen support, mechanical
ventilation, primary pulmonary hypertension
or pregnancy
Observational studies
Brandt et al14 Prospective
observational
study
October 2009
to January
2011
Austria and
Germany
64 (46, 18) 63 years in
both
groups
67 and 61 Patients age >18 years with BP ≥160 mm Hg
(≥150 mm Hg with type 2 diabetes) with at
least 3 antihypertensive drugs. All patients
were on diuretic treatment. Patients with
secondary causes of hypertension were
excluded
Brandt et al15 Prospective
observational
study
October 2009
to September
2011
Austria and
Germany
120 (110, 10) 64 and
65 years
70 and 80 Patients age >18 years with BP ≥160 mm Hg
(≥150 mm Hg with type 2 diabetes) with at
least 3 antihypertensive drugs. Diuretics
were used in 83% of patients. Patients with
secondary causes of hypertension were
excluded
Fatum et al16 NA Germany 21 (15, 6) 67 and
61 years
59 and 60 Patients age >18 years with BP ≥160 mm Hg
(≥150 mm Hg with type 2 diabetes) with at
Continued
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Table 1 Continued
Design Year Country
Number
of participants
(treatment, control) Mean age
Per cent
male Selection criteria and management
Prospective
observational
study
least 3 antihypertensive drugs. Unclear use
of diuretics. Unclear if patients with
secondary causes of hypertensions were
included
Franzen et al13 Prospective
observational
study
NA Germany 27 (21, 6) 63 years NA Patients with BP ≥150 mm Hg with at least 3
antihypertensive drugs. All patients were on
diuretic treatment. Patients with secondary
causes of hypertensions were excluded
Krum et al6 Prospective
observational
study
June 2007 to
November
2008
Australia and
Europe
50 (45, 5) 57 years 58 Patients age >18 years with BP ≥160 mm Hg
(≥150 mm Hg with type 2 diabetes) with at
least 3 antihypertensive drugs. Diuretics
were used in 96% of patients. Patients with
secondary causes of hypertensions were
excluded
Lambert et al20 Observational
study with match
controls
NA Australia 62 treatment, 248
controls
62 years 65 Patients with resistant hypertension.
Diuretics were used in 85% of patients.
Unclear if patients with secondary causes of
hypertension were excluded
Mahfoud et al17 Prospective
observational
study
March 2009 to
May 2010
Australia and
Germany
50 (37, 13) 60 years 74 Patients with age >18 years with BP
≥160 mm Hg (≥150 mm Hg with type 2
diabetes) with at least 3 antihypertensive
drugs. All patients were taking diuretics.
Patients with renal artery abnormality or
stenosis were excluded
Mahfoud et al18 Prospective
observational
study
January 2010
to February
2011
Australia and
Germany
100 (88, 12) 62 years 61 Patients with age >18 years with BP
≥160 mm Hg (≥150 mm Hg with type 2
diabetes) with at least 3 antihypertensive
drugs. All patients had received diuretics.
Patients with renal artery abnormality or
stenosis were excluded
Ukena et al19 Prospective
observational
study
March 2009 to
October 2010
Germany,
Australia, USA
46 (37, 9). 28 from
SYMPLICITY HTN-2
60 years 70 Patients with age >18 years with BP
≥160 mm Hg (≥150 mm Hg with type 2
diabetes) with at least 3 antihypertensive
drugs. Diuretics were used in 87% of
patients. Patients with secondary causes of
hypertension were excluded
AF, atrial fibrillation; BP, blood pressure; eGFR, estimated-glomerular filtration rate; NA, not available.
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Table 2 Treatment, follow-up and results of parallel group studies of renal denervation versus control in resistant hypertension
Clinical trials RD group Control group
Duration of
follow-up Efficacy results
Pokushalov
et al12
RFA of 8–10 W for 2 min up to 6 lesions
and pulmonary vein isolation
Pulmonary vein isolation alone 12 months Reduction at 6 months
Systolic BP
Denervation: −28±7 mm Hg
Control: −5±5 mm Hg
Diastolic BP:
Denervation: −10±6 mm Hg
Control: −3±6 mm Hg
SYMPLICITY
HTN-27
Catheter-based RD with SYMPLICITY
Catheter System
Continuation of anti-hypertensive drugs 1, 3 and
6 months
Systolic BP
RD group (n=52):
Baseline 178±18/96±16 mm Hg. Change at
1 months −20, 3 months −24, 6 months −32
±23 mm Hg.
Control group (n=54): Baseline mm Hg. Change
at 1 months 0, 3 months −4, 6 months 1
±21 mm Hg
Diastolic BP
RD group (n=52):
Baseline 178±17/98±16 mm Hg. Change at
1 months −7, 3 months −8, 6 months −12
±11 mm Hg.
Control group (n=54): Baseline mm Hg. Change
at 1 months 0, 3 months −2, 6 months 0
±10 mm Hg
SYMPLICITY
HTN-38 9
Catheter-based RD with SYMPLICITY
Catheter System
Sham procedure 1, 6 months Systolic BP
RD group (n=364): Baseline office 179.7±16.1.
Value at 6 months: 165.6±23.7.
Change from baseline:−14.13±23.93 mm Hg
Baseline ambulatory: 159.1±13.2. Value at
6 months: 151.8±16.0.
Baseline home: 169.0±15.9. Value at 6 months:
161.1±19.2.
Control group (n=171): Baseline office 180.2
±16.8. Value at 6 months: 168.4±28.6.
Change from baseline −11.74±25.94 mm Hg
Baseline ambulatory: 159.5±13.5. Value at
6 months: 153.9±19.1.
Baseline home: 169.1±16.3. Value at 6 months:
162.8±21.1
Diastolic BP
RD group (n=364): Baseline office 96.5±16.6.
Value at 6 months: 89.5±16.9
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Table 2 Continued
Clinical trials RD group Control group
Duration of
follow-up Efficacy results
Change from baseline −6.75±15.11 mm Hg
Baseline ambulatory:88.0±14.0. Value at
6 months: 83.1±13.7.
Baseline home: 89.6±15.9. Value at 6 months:
86.0±16.6.
Control group (n=171): Baseline office 98.9
±15.8. Value at 6 months: 94.1±17.7
Change from baseline −4.79±17.25 mm Hg.
Baseline ambulatory: 90.9±14.4. Value at
6 months: 87.4±14.6.
Baseline home: 92.9±16.4. Value at 6 months:
90.0±16.4
Observational studies
Brandt et al14 RD with SYMPLICITY or Flex catheter
(Ardian) with up to 6 ablations at 8 W for
2 min each were performed for both renal
arteries
Details of control group not specified 1 and
6 months
Resting systolic BP
RD group (n=46): Baseline 180.7±18.3, 1 month
158.2±17.6, 6 months 152.9±22.4 mm Hg.
Control group (n=18): Baseline 184.5±22.1,
1 month 181.6±26.3, 6 months 182.8
±24.6 mm Hg.
Resting diastolic BP
RD group (n=46): Baseline 95.8±10.1, 1 month
88.6±10.9, 6 months 87±12.9 mm Hg.
Control group (n=18): Baseline 98.2±13.6,
1 month 98±12.7, 6 months 99.8±16.5 mm Hg.
The average number of antihypertensives was
constant for control group 4.8±2.5 while in RD
group it deceased in seven patients (15%) which
led to a change from 4.7±0.5 to 4.5±1.6
antihypertensives
Brandt et al15 RD with catheter (SYMPLICITY and Flex
by Ardian) with up to 6 ablations at 8 W
for 2 min each were performed for both
renal arteries
Details of control group not specified 1, 3 and
6 months
Resting systolic BP
RD group (n=110): Baseline 181±24.7, 1 month
161.1±22.8, 3 month 159.1±22.1, 6 months
152.1±20 mm Hg. Control group (n=10):
Baseline 183.9±21.6, 1 month 181.3±18.5,
3 month 190.6±16.9, 6 months 193.9
±15.4 mm Hg.
Resting diastolic BP
RD group (n=110): Baseline 91.4±12.8, 1 month
87±14, 3 months 84±13.1, 6 months 83.7
±13.5 mm Hg. Control group (n=10): Baseline
Continued
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Table 2 Continued
Clinical trials RD group Control group
Duration of
follow-up Efficacy results
95.3±11.5, 1 month 97.1±18.9, 3 months 104.6
±15.6, 101.5±17.9 mm Hg
Fatum et al16 Catheter-based bilateral RD Untreated controls 6 months At 6 months, office BP reduced by −26/
−7 mm Hg in the RD group (n=15) and no
significant changes in the control group (n=6).
Baseline 170/89 mm Hg for RD group and 172/
93 mm Hg for control group
Franzen et al13 Percutaneous RD with a RFA catheter
system
Details of control group not specified 3 and
6 months
Systolic BP
RD group (n=21): Baseline 156±13, 3 months
145±13, 6 months 148±17 mm Hg.
Control group (n=6): Values did not change
significantly
Krum et al6 RD with catheter (SYMPLICITY) with
ablations at 8 W for 2 min each were
performed for both renal arteries
Patients with renovascular abnormalities
such as severe renal artery stenosis,
previous renal stenting/ angioplasty or
known dual renal arteries
1, 3, 6, 9
and
12 months
Mean reduction in office blood pressures for
treatment group were −14/−10 (95% CI 4/3),
−21/−10 (7/4), −22/−11 (10/5), −24/−11 (9/5)
and −27/−17 at 1, 3, 6, 9 and 12 months.
Mean reduction in office blood pressures were
+3/−2, +2/+3, +14/+9, +26/+17 at 1, 3, 6 and 9.
At baseline average of 4.7 hypertensive
medications and 96% had diuretics. This did not
change at follow-up
Lambert et al20 Bilateral renal nerve ablation by a
radiofrequency catheter (SYMPLICITY by
Ardian)
Matched normotensive and controlled
blood pressure controls from the
Australian Diabetes, Obesity, and Lifestyle
database
3 months Post RD BP had reduced by −16±4 and −6
±2 mm Hg. Baseline BP was 166±3 and 88
±2 mm Hg in RD group (n=62)
Mahfoud et al17 Treatment catheter (SYMPLICITY and
Flex by Ardian) with RFA lasting up to
2 min with low power of 8 W to obtain up
to 6 ablations
Medical therapy 1 and
3 months
Systolic BP
RD group (n=37): Baseline 177±3.Change at
1 month −28±2, 3 months −32±4 mm Hg.
Control group (n=13): Baseline 184±5. Change
at 1 month −8±6, 3 months −5±5 mm Hg.
Diastolic BP
RD group (n=37): Baseline 96±6. Change at
1 month −10±2, 3 months −12±2 mm Hg.
Control group (n=13): Baseline 94±4. Change at
1 month −4±4, 3 months −3±3 mm Hg.
While patients were instructed not to change
their medications, 13 patients in the treated
group had to reduce antihypertensives because
of symptoms of hypotension
Mahfoud et al18 Treatment catheter (SYMPLICITY and
Flex by Ardian) with ablations in both
Details of control group not specified 3 and
6 months
Systolic BP
RD group (n=88): Baseline 174±2 mm Hg.
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Table 2 Continued
Clinical trials RD group Control group
Duration of
follow-up Efficacy results
renal arteries with up to 8 ablations for
2 min with a maximum of 8 W
Change at 3 month −22.7±2.3, 6 months −26.6
±2.5 mm Hg. Control group (n=12): Baseline 184
±7 mm Hg. Change at 3 month −7.2±7.6,
6 months −4.4±6.2 mm Hg.
Diastolic BP
RD group (n=88): Baseline 95±2 mm Hg.
Change at 3 month −7.7±1.3, 6 months −9.7
±1.5 mm Hg. Control group (n=12): Baseline 97
±5 mm Hg. Change at 3 month −4.1±4.7,
6 months −3.0±4.3 mm Hg.
Number of antihypertensives was 5.7±0.2. At
3 months follow-up 18 patients (18%) had
reduced antihypertensives use and 7 (7%) had
increased antihypertensive use
Ukena et al19 Catheter-based RD with SYMPLICITY
Catheter System
Details of control group not specified 3 months Systolic BP
RD group (n=37): Baseline 172±24, 3 months
141±21 mm Hg. Change at 3 months 31
±13 mm Hg. Control group (n=9): Baseline 166
±23, 3 months 166±25 mm Hg. Change at
3 months 0±17 mm Hg.
Diastolic BP
RD group (n=37): Baseline 94±19, 3 months 85
±16 mm Hg. Change at 3 months: −9
±13 mm Hg. Control group (n=9): Baseline 90±7,
3 months 89±9 mm Hg. Change at 3 months −1
±5 mm Hg
BP, blood pressure; RD, renal denervation; RFA, radiofrequency ablation.
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data from two unblinded trials of lower quality showed
signiﬁcant reduction in change in systolic (−27.36 95%
CI −37.08 to −24.61 mm Hg) and diastolic blood pres-
sure (−9.62 95% CI −14.51 to −4.72 mm Hg). The sub-
group testing proves signiﬁcant differences between the
two data set and conﬁrms that moderate-high risk of
bias studies give signiﬁcant effects while low risk of bias
studies do not. The results are presented in ﬁgure 1.
Results from other observational studies are shown in
table 2. Systolic and diastolic blood pressure reductions
with renal denervation were reported by all of these
studies.6 13–20
Only a few studies reported adverse events associated
with renal denervation (see online supplementary
appendix 4). The SYMPLICITY HTN-3 trial was the only
study to report cardiovascular events at 6 months
follow-up. There was no signiﬁcant difference between
treatment and control group in terms of death, myocar-
dial infarction, new onset renal disease, stroke and
hypertensive crisis or emergency. The most commonly
reported adverse event was a pseudoaneurysm at the
femoral access site and this was reported in four
studies.6 7 17 18 Other adverse events reported included
renal artery dissection,6 contrast medium allergic reac-
tion,18 postprocedural hypotension,7 intraprocedural
bradycardia7 and ﬁve cases of hypertensive emergencies
requiring admission to hospitalisation (three in the
renal denervation group and two in the control group).7
DISCUSSION
Our systematic review of three randomised controlled
trials with 688 participants has suggested a wide range of
reported outcomes associated with the treatment of
drug-resistant hypertension by renal denervation. Data
derived from the highest quality single-blind, rando-
mised, sham-controlled trial (SYMPLICITY HTN-3) sug-
gests that renal denervation does not produce
signiﬁcant reductions in systolic blood pressure and dia-
stolic blood pressure while lower quality non-blinded
randomised controlled trials and observational studies
suggest that there are signiﬁcant reductions in blood
pressure with renal denervation. These latter studies are
confounded by signiﬁcant bias.
The choice of control arm is an important consider-
ation when evaluating studies of renal denervation. The
SYMPLICITY HTN-3 trial was the ﬁrst randomised con-
trolled trial to use both a sham-control group and blind-
ing. This raises the issue of possible bias during outcome
assessment in the other two randomised controlled trials
and non-blinded observational studies where there may
have been major differences in the subsequent monitor-
ing and follow-up, or medication adherence and use of
cointerventions among patients who had undergone
renal denervation. Inadequate blinding may cause bias
through differences in recording blood pressure.
Interestingly, in the SYMPLICITY studies, the magnitude
of reduction in blood pressure following renal
Figure 1 Mean difference in systolic and diastolic blood pressure for the three randomised controlled trials at follow-up
postrenal denervation.
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denervation was also signiﬁcantly greater if recorded
through ofﬁce measurements compared to ambulatory
measurements. For example, the decrease in systolic
blood pressure at 6 months following renal denervation
was between 25 and 30 mm Hg for ofﬁce blood pressure
measurements while on 24 h ambulatory monitoring, it
was approximately 10 mm Hg.6 7 21 The reasons for
these differences in magnitude of beneﬁt depending on
the modality by which blood pressure is measured
remain unclear although ambulatory blood pressure
monitors operate in a blinded fashion whereas ofﬁce
blood pressure measurements as in the SYMPLICITY
studies are recorded in an unblinded fashion and were
therefore subject to bias. The failure of the SYMPLICITY
HTN-3 trial to meet the primary blood pressure end
point is of interest. The blinded, sham nature of the
study would remove many of the biases included in
unblinded denervation studies, such as the possibility of
decreased medication adherence in patients randomised
to the medical treatment arm with improved adherence in
the treatment arm. Ofﬁce-based blood pressure measure-
ments are a signiﬁcant source of major bias,22 with signiﬁ-
cant potential for regression towards the mean. Patients
enrolled in hypertension studies have a better chance of
meeting the inclusion criteria of the study on a day
when their blood pressure is above their own long-term
mean. If the patient’s blood pressure is then followed
up, its average will tend to return to that individual’s
true mean pressure, even if there was no intervention
introducing bias.22 One aspect that has drawn comment
regarding the failure of the SYMPLICITY HTN-3 trial to
show efﬁcacy in the treatment of drug-resistant hyperten-
sion relates to whether or not participants achieved
optimal renal denervation and the potential for differ-
ent subgroups of patients to respond differently to the
denervation procedure.23–25 Reductions in blood pres-
sure were observed in speciﬁc subgroups of patients par-
ticularly in non-black patient cohorts and in younger
patients, although the absolute reduction in BP in these
subgroups was small with an order of magnitude around
5–6 mm Hg. Whether this represents differences in the
importance of the sympathetic nerve system in the
pathophysiology of drug-resistant hypertension in these
cohorts or the efﬁcacy of the procedure in disrupting
neural pathways in these patients remains unclear.
While angiographic markers of successful delivery of
energy causing vascular disruption (notching) can be
seen during the denervation procedure, no reliable
markers of renal denervation are available, hence the
completeness and extent of renal nerve disruption is
uncertain. The unipolar nature of the SYMPLICITY
system used in this trial makes it more technically chal-
lenging to ensure true circumferential ablation, com-
pared to more contemporary multipolar systems, hence
the efﬁcacy of the treatment will be highly operator
dependent. Interestingly, the SYMPLICITY HTN-3 trial
reported that outcomes between operators performing
ﬁve or more procedures and those performing fewer
than ﬁve procedures were similar, with no evidence of a
learning curve for high-volume operators when earlier
procedures were compared with later ones. It remains
unclear whether similar results will be seen with other
multipolar systems currently on the market, which have
been designed to enable the delivery of a circumferen-
tial ablation to the renal artery, or whether the lack of
efﬁcacy reported with the SYMPLICITY system repre-
sents a class effect. An interesting ﬁnding of the
SYMPLICITY HTN-3 was that major reductions in blood
pressure, which were not present in the previous
SYMPLICITY trials, were observed in the control group.
One explanation for this was that there was greater
exposure to spironolactone in SYMPLICITY HTN-3.25
The other explanations may relate to the difference in
control arm and the use of sham operation, which may
lead to improved adherence to medication and the
placebo effect.
Despite renal denervation being undertaken predom-
inantly in patients with drug-resistant hypertension who
are at signiﬁcant risk from future cardiovascular events,
the very nature of an invasive procedure itself may pre-
dispose to potential cardiovascular complications.
SYMPLICITY HTN-3 is the ﬁrst high-quality study to
demonstrate the safety of the procedure in terms of car-
diovascular disease and mortality end points, with no sig-
niﬁcant increases in major adverse events, deﬁned as
death from any cause, end-stage renal disease, embolic
events resulting in end-organ damage, renal-artery or
other vascular complications, hypertensive crisis within
30 days or new renal-artery stenosis of more than 70%
within 6 months following the denervation procedure.
A few other studies have described procedure-related
complications, the most common of which being access
site related complications at the femoral access such as
haematomas, pseudoaneurysms, etc (approximately
2%), with two reported cases of renal artery dissection
(<1%) that needed renal artery stenting.6 21 26
Furthermore, concerns have been raised regarding the
impact of renal denervation on renal function.27 There
is limited long-term evidence from the SYMPLICITY
HTN-1, that there was a decrease in estimated-
glomerular ﬁltration rate after renal denervation but it
is unclear if this is related to changes in medication
after the procedure.28
Our systematic review has a few strengths. We were
able to identify studies that reported mean differences
and SDs that enable statistical pooling of results. We
have considered studies of different design that varied in
their risk of bias. Our systematic review relies on the
most up-to-date evidence, including data derived from
the largest, highest quality randomised controlled trial.
Study limitations
The major limitations of our review stem from only one
high-quality study; the majority were underpowered and
longer follow-up is needed. Furthermore, there may
have been overlap of some of the studies, for example,
10 Kwok CS, Loke YK, Pradhan S, et al. Open Heart 2014;1:e000092. doi:10.1136/openhrt-2014-000092
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both the Ukena19 and Mahfoud17 18 analyses contained
a small number of patients that were enrolled as part of
the SYMPLICITY HTN-1 and/or SYMPLICITY HTN-2
studies. The sample sizes of studies included were as
small as 20 patients, which are insufﬁcient to capture
safety events. Non-blinded studies have a risk of bias in
outcome assessment and the heterogeneity and lack of
management description of the control group is
another limitation. These studies lack a standardised
diagnostic work-up to exclude secondary hypertension
and do not include ambulatory out-of-the-ofﬁce blood
pressure measurement to exclude white coat hyperten-
sion or a formal assessment of adherence. Finally, there
is the potential for publication bias and selective
outcome reporting, particularly with a new technology
such as renal denervation where investigators who found
no beneﬁt from renal denervation may have decided
either to not publish the data or to only report selected
signiﬁcant ﬁndings.
In summary, evidence for the efﬁcacy of renal denerv-
ation using catheter-based systems in reducing blood
pressure in resistant hypertension is derived from
unblinded studies that are at risk of bias. The highest
quality single blinded randomised controlled trial did
not show efﬁcacy in ofﬁce blood pressure reduction,
although it did meet its safety end point. Future studies
investigating the efﬁcacy of renal denervation in the
treatment of drug-resistant hypertension should be
undertaken in a blinded manner, with sham procedures
in the control group and ambulatory monitoring to
reduce the potential for bias.
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